

# SENATE BILL 954

J1

3lr2929  
CF HB 571

---

By: **Senator Klausmeier**

Introduced and read first time: February 24, 2023

Assigned to: Rules

---

## A BILL ENTITLED

1 AN ACT concerning

2 **Overdose Response Program – Opioid Overdose Reversal Drugs – Choice of**  
3 **Formulation and Dosage**

4 FOR the purpose of requiring the Maryland Department of Health to allow certain entities  
5 provided opioid overdose reversal drugs by the Department under the Overdose  
6 Response Program to choose the formulation or dosage of opioid overdose reversal  
7 drugs approved by the federal Food and Drug Administration with which the entity  
8 is to be provided; and generally relating to the Overdose Response Program.

9 BY repealing and reenacting, with amendments,  
10 Article – Health – General  
11 Section 13–3103  
12 Annotated Code of Maryland  
13 (2019 Replacement Volume and 2022 Supplement)

14 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,  
15 That the Laws of Maryland read as follows:

16 **Article – Health – General**

17 13–3103.

18 (a) The Department shall adopt regulations necessary for the administration of  
19 the Program.

20 (b) The Department may:

21 (1) Collect fees necessary for the administration of the Program;

22 (2) Authorize private or public entities to conduct education and training  
23 on opioid overdose recognition and response that include:

---

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.



1 (i) Education on recognizing the signs and symptoms of an opioid  
2 overdose;

3 (ii) Training on responding to an opioid overdose, including the  
4 administration of opioid overdose reversal drugs approved by the federal Food and Drug  
5 Administration; and

6 (iii) Access to opioid overdose reversal drugs approved by the federal  
7 Food and Drug Administration and the necessary supplies for the administration of the  
8 opioid overdose reversal drugs;

9 (3) Develop guidance regarding the content of educational training  
10 programs conducted by private or public entities; and

11 (4) Collect and report data on the operation and results of the programs.

12 (c) An individual is not required to obtain training and education on opioid  
13 overdose recognition and response from a private or public entity under subsection (b) of  
14 this section in order for a pharmacist to dispense an opioid overdose reversal drug approved  
15 by the federal Food and Drug Administration to the individual.

16 (d) (1) Subject to the limitations of the State budget, the Department shall  
17 purchase and provide opioid overdose reversal drugs approved by the federal Food and  
18 Drug Administration, at no cost, to the providers who are required to offer opioid overdose  
19 reversal drugs approved by the federal Food and Drug Administration under § 8–408 or §  
20 19–310.3 of this article.

21 (2) An entity required to offer an opioid overdose reversal drug approved  
22 by the federal Food and Drug Administration under § 8–408 or § 19–310.3 of this article  
23 may provide an opioid overdose reversal drug approved by the federal Food and Drug  
24 Administration only if the opioid overdose reversal drug approved by the federal Food and  
25 Drug Administration is provided by the Department.

26 **(3) THE DEPARTMENT SHALL ALLOW AN ENTITY THAT IS PROVIDED**  
27 **WITH OPIOID OVERDOSE REVERSAL DRUGS BY THE DEPARTMENT UNDER THIS**  
28 **SUBSECTION TO CHOOSE THE FORMULATION OR DOSAGE OF OPIOID OVERDOSE**  
29 **REVERSAL DRUGS APPROVED BY THE FEDERAL FOOD AND DRUG ADMINISTRATION**  
30 **WITH WHICH THE ENTITY IS TO BE PROVIDED.**

31 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect  
32 October 1, 2023.